News

ReCor Medical disclosed updated data for the REDUCE First-In-Man clinical study of its CE-marked Paradise (percutaneous renal denervation system) ultrasound platform, which is...

April 6, 2012 — The U.S. anticoagulant market is on the verge of a major shift in clinical practice, transitioning from a market dominated by a single injectable anticoagulant to a highly...

April 4, 2012 — Medtronic Inc. announced that the Symplicity renal denervation system provides safe, significant and sustained blood pressure reduction up to three years in patients with treatment...

It seems a picture is worth more than a thousand words for people who see evidence of coronary artery disease, the most common type of heart disease in men and women. Simply seeing a build-up of...

Internet-based telemedicine systems appear to lead to more appropriate and effective pharmacotherapy, better blood pressure control and an overall reduction in cardiovascular risk compared to...

March 29, 2012 — Adding vorapaxar, an investigational platelet blocker, to standard antiplatelet therapy significantly reduces the risk of recurrent cardiovascular events in a specific group of...

March 29, 2012 — A three-pronged intervention in Brazilian public hospitals significantly improved physician adherence to evidence-based protocols for treating acute coronary syndrome (ACS),...

March 27, 2012 – Researchers found the antiplatelet drug abciximab significantly decreased damage to the heart muscle in patients with ST-segment-elevation myocardial infarction (STEMI), the most...

March 19, 2012 – Individuals suffering from chronic heart failure (CHF) can look forward to the appearance of many new drug options over the next few years and place hope in a cure through future...

March 9, 2012 - Researchers say venom from the green mamba snake may aid in the preservation of cardiac and renal function following serious cardiovascular events, such as heart attack and acute...

March 8, 2012 — Transgenomic Inc. announced the publication of a new study by researchers at Vanderbilt University that further validates the role of both genes found in the company’s PGxPredict:...

March 7, 2012 — The U.S. Food and Drug Administration (FDA) notified healthcare professionals of updates to the prescribing information concerning interactions between protease...

February 29, 2012 — Vessix Vascular Inc. announced initial patient treatments in the international multi-center Reduce-HTN renal denervation clinical study for uncontrolled hypertension.

February 28, 2012 — Janssen Research and Development LLC announced that the U.S. Food and Drug Administration (FDA) has assigned a priority review designation to the supplemental new drug...

February 23, 2012 — AstraZeneca announced that the American College of Chest Physicians (ACCP) has updated its guidelines on Antithrombotic Therapy and Prevention of Thrombosis to include a...

PARADISE

February 20, 2012 — ReCor Medical announced that its Paradise percutaneous ultrasound renal denervation system for achieving rhas received the CE mark. Paradise is designed to treat patients with...

February 20, 2012 — Biopharmaceutical company Celladon Corp. this week completed a $43 million equity financing to advance its lead investigational drug candidate Mydicar for the treatment of...

February 15, 2012 — Vessix Vascular Inc., developer of a novel percutaneous radiofrequency (RF) balloon catheter technology, announced that it will make its first detailed public presentation of...

February 15, 2012 — Medtronic Inc. announced the start of two clinical initiatives evaluating the broader, real-world clinical use of the company’s Symplicity renal denervation system across...

 

January 19, 2012 – New findings from a research study led by physicians at Scripps Health reveal that the investigational drug cangrelor can achieve very fast blood thinning effects...